Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
Demo Company
PURITAN MEDICAL

Partnership Established to Decode Bowel Disease

By BiotechDaily International staff writers
Posted on 25 Aug 2014
23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity, and response to treatments for IBD.

Approximately 1.4 million people in the United States alone suffer from IBD, according to estimates from the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). Although IBD is known to be more common in developed countries, the exact cause of this chronic disorder is still not determined, and there is no cure.

The collaboration represents a novel effort for both companies designed to study the underlying genetics of IBD and it is hoped that the project will in the end lead to possible new or optimized treatments for IBD. “We are excited to team up with Pfizer to take an innovative, consumer-centered approach to try to understand the fundamentals of inflammatory bowel disease and the variability of treatment response,” said 23andMe CEO and co-founder Anne Wojcicki.

“Pfizer is committed to bringing forward new treatments for patients suffering with IBD,” said Jose Carlos Gutierrez-Ramos, senior vice president, biotherapeutics research and development, Pfizer. “By enhancing our understanding of the underlying biology of the disease, we hope to better support our clinical research activities and development programs.”

About 23andMe 23andMe helps individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company’s Personal Genome Service enables individuals to gain deeper insights into their ancestry and inherited traits.

Related Links:

23andMe
Pfizer



Channels

Genomics/Proteomics

view channel
Image: An activated PTEN dimer that contains two non-mutant proteins (A) can transform the functional lipid (D) on the cellular membrane (E) into a chemical form that tunes down cancer predilection. Dimers that contain a mutated protein (B) or PTEN monomers cannot transform the functional lipid (Photo courtesy of Carnegie Mellon University).

PTEN Requires a Stable Dimer Configuration to Effectively Suppress Tumor Growth

Molecular structural analysis has shown that the PTEN (phosphatase and tensin homolog) tumor suppressor can function effectively only when two wild-type alleles are present to form a stable dimer that... Read more

Lab Technologies

view channel
Image: The ChilliBlock modular system for precise, controlled cooling and heatingof biological samples (Photo courtesy of Asynt).

Modular Cooling/Heating System Safeguards Temperature-Sensitive Biological Samples

A new modular system designed for precise, controlled cooling and heating of biological samples in microplates, vials and Eppendorf tubes is now available for biotech, clinical, and life science laboratories.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.